The Helping to End Addiction Long-Term Initiative℠, or NIH HEAL Initiative℠, recently published 2 funding opportunity announcements soliciting applications focused on sickle cell disease (SCD) pain management. The effort is co-led by the National Center for Complementary and Integrative Health and the National Heart, Lung, and Blood Institute, with support from other NIH Institutes, Centers, and Offices.

• RFA-AT-23-001, “HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain” (UG3/UH3, Clinical Trials Optional) will support multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic SCD pain management in healthcare systems that serve the SCD population.
• RFA-AT-23-002, “HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement” (UG3/UH3, Clinical Trial Required), will support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic SCD pain management, allowing continued opioid pain management as needed.